BioSpace News Archive

The Board of Directors of Bioretec Ltd has on 20 October 2023 decided, on the basis of the authorization received from the company’s Annual General Meeting on 26 May 2023, to establish a new option program as an incentive scheme for the employees and consultants and members of the company’s Key Opinion Leader group of the company and its subsidiaries.

Foundation Medicine Inc. and Roche today announced that they will present the results from a randomized, global precision oncology study designed to prospectively assess the efficacy and safety of molecularly-guided therapy for patients with unfavorable subset cancer of unknown primary (CUP).

Genprex, Inc. today announced that it will host a virtual key opinion leader (KOL) event highlighting the current state of lung cancer treatments and the challenges facing patients.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new individual patient response data showing nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in Psoriasis Area and Severity Index (PASI).

Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years of adjuvant Verzenio® (abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence.

Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference.

KEYTRUDA ® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC).

Journey Medical Corporation today announced data from a comparative bioavailability (bridging) study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg). DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Therapeutic Solutions International, Inc. (TSOI), announced today the successful first treatment of a patient with FloraStilbene™, a patent pending formulation of the abortion pill’s active ingredient, RU486, and pterostilbene.

From October 23 through October 27, generative art platform Art Blocks will host reGEN — an exclusive sale of works by five leading artists from around the world, supported by Right Click Save.